Exelixis: Zanzalintinib Sees Mixed Progress, Cabozantinib Grinds Upwards

Exelixis (EXEL) continues to grow cabozantinib revenues, yet its pipeline asset zanzalintinib faces mixed clinical progress. While STELLAR-303 showed success for zanzalintinib, the magnitude of clinical benefit remains undisclosed. Conversely, zanzalintinib underperformed in head and neck cancer during STELLAR-305 Phase 2, prompting development curtailment in that indication. This mixed pipeline performance, despite existing revenue growth, has led to a muted market reaction, highlighting investor caution regarding future growth drivers.

Analysis

Exelixis presents a mixed clinical and commercial picture. While the company's existing revenue driver, cabozantinib, continues to exhibit steady growth, its key pipeline asset, zanzalintinib, has produced conflicting trial results, creating uncertainty around future growth prospects. The STELLAR-303 trial for zanzalintinib has been declared a success, but the critical detail regarding the magnitude of clinical benefit remains undisclosed, making it difficult to assess its commercial potential. This ambiguity is compounded by a clear setback in the STELLAR-305 trial, where zanzalintinib failed to show a significant benefit in head and neck cancer, leading the company to curtail development for that indication. The market's muted reaction reflects this balance of a solid commercial base against a pipeline with significant unresolved questions, indicating that investors are awaiting more definitive data before pricing in future upside.

Key Decisions for Investors

• Investors should closely monitor for the release of detailed data from the STELLAR-303 trial, as the size of zanzalintinib's clinical benefit will be a primary catalyst for the stock.
• It is prudent to re-evaluate valuation models to reflect the reduced total addressable market for zanzalintinib following the curtailment of development in head and neck cancer.
• Given the pipeline uncertainty, consider the stock's current valuation as largely supported by the stable cabozantinib franchise, with zanzalintinib representing a high-risk, high-reward option dependent on future data points.